Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers

Journal of Clinical Pharmacology

Volumn 38, Issue 8, 1998, Pages 702-707

  Vachharajani, Nimish N ^a   Shyu, Wen Chyi ^a   Chando, Theodore J ^a   Everett, Donald W ^a   Greene, Douglas S ^a   Barbhaiya, Rashmi H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRBESARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CLEARANCE; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 3543022059     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1998.tb04809.x     Document Type: Article

References (17)

1. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al: Angiotensin II receptors and angiotensin II antagonists. Pharmacol Rev 1993;45:205-251.
2. Eberhardt RT, Kevak RM, Kang PM, Frishman WH: Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. J Clin Pharmacol 1993;33:1023-1038.
3. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Suavely DB, et al: Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 1994;12:1387-1393.
4. Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, et al: Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993;265:826-834.
5. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-29.
6. Ribstein J, Sissman J, Picard A, Bouroudian M, Mimran A: Effect on the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the reninangiotensin system in sodium replete normal subjects (abstract). J Hypertens 1994;12(suppl 3):131.
7. Necciari J, Denolle T, Le Croz F, Donazello Y Pastor G, Sissman J: Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man (abstract). J Hypertens 1994;12(suppl 3):88.
8. Vachharajani N, Shyu WC, Smith R, Chang S-Y, Greene D, Barbhaiya R: The effects of age and gender on the pharmacokinetics of irbesartan (abstract). Pharm Res 1995;12(suppl):388.
9. Marino MR, Langenbacher KM, Ford NF, Uderman HD: Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects, J Clin Pharmacol 1998;38:246-255.
10. Chang S-Y, Whigan DB, Vachharajani NN, Patel R: High performance liquid Chromatographic assay for the quantitation of irbesartan (SR 47436/BMS-186295) in human plasma and urine. J Chromatogr B 1997;702:149-155.
11. Gibaldi M, Perrier D: Pharmacokinetics. Second edition, New York: Marcel Dekker, 1982.
12. Riegelman S, Collier P: The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-534.
13. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD: Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-649.
14. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59-71.
15. Chando T, Everett D, Kahle AD, Starrett AM, Vachharajani N, Shyu WC, et al: Biotransformation of irbesartan in man. Drug Metab Dispos 1982;26:408-417.
16. McLean AJ, Morgan DJ: Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991;21:42-69.
17. Christopher B, Libon R, Cazaubon C, Nisato D, Manning A, Chatelain P: Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action. Eur J Pharmacol 1995;281:161-171.